Role of brain protection drug in epilepsy surgery
Not Applicable
Active, not recruiting
- Conditions
- Health Condition 1: null- Patients Undergoing Epilepsy Surgery
- Registration Number
- CTRI/2016/10/007406
- Lead Sponsor
- ALL INDIA INSTITUTE OF MEDICAL SCIENCES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1.Consenting patients
2.Intractable epilepsy posted for epilepsy surgery under general anesthesia being operated by single neurosurgeon (PSC)
3.ASA grade I & II
Exclusion Criteria
1.Non consenting patients
2.Known hypersensitivity to dexmedetomedine
3.Patients with heart block
4.Patients with hypotension
5.Pregnant patients
6.Patients with renal/hepatic disease
7.Patients on beta blockers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ï?·To study the effect of dexmedetomidine and placebo on cerebral injury markers(S100B & NSE) in patients undergoing epilepsy surgeryTimepoint: 1.Preoperative <br/ ><br>2.Postoperative <br/ ><br>3.24 hours <br/ ><br>4.48 hours
- Secondary Outcome Measures
Name Time Method ï?·To find relation between s100b and NSE in the postoperative period <br/ ><br>ï?·To find relation between seizure control with markers of cerebral ischemia <br/ ><br>ï?·To find relationship between use of dexmedetomidine and postoperative seizure controlTimepoint: Preoperative period <br/ ><br>Immediate Postoperative <br/ ><br>24 Hours Postoperative <br/ ><br>AT TIME OF DISCHARGE